Pigment epithelium‑derived factor inhibits advanced glycation end product‑induced proliferation, VEGF and MMP‑9 expression in breast cancer cells via interaction with laminin receptor

Tsuruhisa,Shiori; Matsui,Takanori; Koga,Yoshinori; Sotokawauchi,Ami; Yagi,Minoru; Yamagishi,Sho-Ichi

doi:10.3892/ol.2021.12890

Pigment epithelium‑derived factor inhibits advanced glycation end product‑induced proliferation, VEGF and MMP‑9 expression in breast cancer cells via interaction with laminin receptor

Authors:
- Shiori Tsuruhisa
- Takanori Matsui
- Yoshinori Koga
- Ami Sotokawauchi
- Minoru Yagi
- Sho-Ichi Yamagishi
View Affiliations

Affiliations: Department of Pediatric Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan, Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan, Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo 142‑8666, Japan
Published online on: June 30, 2021 https://doi.org/10.3892/ol.2021.12890
Article Number: 629

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pigment epithelium‑derived factor (PEDF) is one of the adipocytokines with multifaceted functions, which may serve a role in the development of various types of cardiometabolic disorders. Advanced glycation end products (AGEs) have been shown to contribute to numerous aging‑associated disorders, such as cancer. However, it remains unclear whether and how PEDF exerts antitumor effects in AGE‑exposed human breast cancer MCF‑7 cells, and therefore this was explored in the present study. NADPH oxidase activity was measured with luciferase assay, while gene and protein expression levels were evaluated with quantitative PCR and western blot analysis, respectively. AGEs significantly increased NADPH oxidase‑driven superoxide generation, cytochrome b‑245 β chain (gp91phox) and receptor for AGE (RAGE) mRNA expression, proliferation, mRNA and protein expression levels of vascular endothelial growth factor (VEGF), and matrix metalloproteinase (MMP)‑9 mRNA expression in MCF‑7 cells, all of which were dose‑dependently inhibited by PEDF. Neutralizing antibody against laminin receptor (LR‑Ab) significantly blocked these beneficial effects of PEDF in AGE‑exposed MCF‑7 cells. Furthermore, as in AGE‑treated cells, PEDF dose‑dependently inhibited the NADPH oxidase‑driven superoxide generation, gp91phox, RAGE and MMP‑9 mRNA expression, proliferation, mRNA and protein expression levels of VEGF in non‑treated control MCF‑7 cells, and these effects were also reversed by LR‑Ab. LR levels were not affected by the treatment with AGEs, PEDF or LR‑Ab. The present study suggested that PEDF may exert antitumor effects in AGE‑exposed breast cancer cells by suppressing NADPH oxidase‑induced ROS generation and VEGF and MMP‑9 expression via interaction with LR. Since PEDF expression is decreased in breast cancer tissues, pharmacological upregulation or restoration of PEDF may inhibit the growth and metastasis of breast cancer.

View Figures

View References

1	Tombran-Tink J, Chader CG and Johnson LV: PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res. 53:411–414. 1991. View Article : Google Scholar : PubMed/NCBI
2	Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W and Bouck NP: Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science. 285:245–248. 1999. View Article : Google Scholar : PubMed/NCBI
3	Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, Katai M, Yan L, Suzuma K, West K, et al: Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci. 43:821–829. 2002.PubMed/NCBI
4	Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M and Inoue H: Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res. 65:186–190. 2003. View Article : Google Scholar : PubMed/NCBI
5	Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J and Crawford SE: Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med. 9:774–780. 2003. View Article : Google Scholar : PubMed/NCBI
6	Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, et al: Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem. 281:20213–20220. 2006. View Article : Google Scholar : PubMed/NCBI
7	Fujimura T, Yamagishi S, Ueda S, Fukami K, Shibata R, Matsumoto Y, Kaida Y, Hayashida A, Koike K, Matsui T, et al: Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol Dial Transplant. 24:1397–1406. 2009. View Article : Google Scholar : PubMed/NCBI
8	Matsui T, Higashimoto Y, Taira J and Yamagishi S: Pigment epithelium-derived factor (PEDF) binds to caveolin-1 and inhibits the pro-inflammatory effects of caveolin-1 in endothelial cells. Biochem Biophys Res Commun. 441:405–410. 2013. View Article : Google Scholar : PubMed/NCBI
9	Matsui T, Nishino Y, Ojima A, Maeda S, Tahara N and Yamagishi S: Pigment epithelium-derived factor improves metabolic derangements and ameliorates dysregulation of adipocytokines in obese type 2 diabetic rats. Am J Pathol. 184:1094–1103. 2014. View Article : Google Scholar : PubMed/NCBI
10	Takenaka K, Yamagishi S, Matsui T, Nakamura K, Jinnouchi Y, Yoshida Y, Ueda S, Katsuki Y, Katsuda Y and Imaizumi T: Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: A possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis. 197:25–33. 2008. View Article : Google Scholar : PubMed/NCBI
11	Yamagishi SI and Matsui T: Pigment epithelium-derived factor: A novel therapeutic target for cardiometabolic diseases and related complications. Curr Med Chem. 25:1480–1500. 2018. View Article : Google Scholar : PubMed/NCBI
12	Abe R, Shimizu T, Yamagishi S, Shibaki A, Amano S, Inagaki Y, Watanabe H, Sugawara H, Nakamura H, Takeuchi M, et al: Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol. 164:1225–1232. 2004. View Article : Google Scholar : PubMed/NCBI
13	Takenaka K, Yamagishi S, Jinnouchi Y, Nakamura K, Matsui T and Imaizumi T: Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci. 77:3231–3241. 2005. View Article : Google Scholar : PubMed/NCBI
14	Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, Polsky C and Volpert OV: Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res. 15:1655–1663. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhou D, Cheng SQ, Ji HF, Wang JS, Xu HT, Zhang GQ and Pang D: Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol. 136:1719–1727. 2010. View Article : Google Scholar : PubMed/NCBI
16	Seki R, Yamagishi S, Matsui T, Yoshida T, Torimura T, Ueno T, Sata M and Okamura T: Pigment epithelium-derived factor (PEDF) inhibits survival and proliferation of VEGF-exposed multiple myeloma cells through its anti-oxidative properties. Biochem Biophys Res Commun. 431:693–697. 2013. View Article : Google Scholar : PubMed/NCBI
17	Becerra SP and Notario V: The effects of PEDF on cancer biology: Mechanisms of action and therapeutic potential. Nat Rev Cancer. 13:258–271. 2013. View Article : Google Scholar : PubMed/NCBI
18	Gong Q, Qiu S, Li S, Ma Y, Chen M, Yao Y, Che D, Feng J, Cai W, Ma J, et al: Proapoptotic PEDF functional peptides inhibit prostate tumor growth-a mechanistic study. Biochem Pharmacol. 92:425–437. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhou D, Zhang M, Xu P, Yu Y, Ye G, Zhang L and Wu A: Expression of pigment epithelium-derived factor is associated with a good prognosis and is correlated with epithelial-mesenchymal transition-related genes in infiltrating ductal breast carcinoma. Oncol Lett. 11:116–124. 2016. View Article : Google Scholar : PubMed/NCBI
20	Yamagishi SI, Koga Y, Sotokawauchi A, Hashizume N, Fukahori S, Matsui T and Yagi M: Therapeutic potential of pigment epithelium-derived factor in cancer. Curr Pharm Des. 25:313–324. 2019. View Article : Google Scholar : PubMed/NCBI
21	Yamagishi S: Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders. Rejuvenation Res. 15:564–572. 2012. View Article : Google Scholar : PubMed/NCBI
22	Sadowska-Bartosz I and Bartosz G: Effect of glycation inhibitors on aging and age-related diseases. Mech Ageing Dev. 160:1–18. 2016. View Article : Google Scholar : PubMed/NCBI
23	Rowan S, Bejarano E and Taylor A: Mechanistic targeting of advanced glycation end-products in age-related diseases. Biochim Biophys Acta Mol Basis Dis. 1864:3631–3643. 2018. View Article : Google Scholar : PubMed/NCBI
24	Yamagishi SI and Matsui T: Therapeutic potential of DNA-aptamers raised against AGE-RAGE axis in diabetes-related complications. Curr Pharm Des. 24:2802–2809. 2018. View Article : Google Scholar : PubMed/NCBI
25	Rungratanawanich W, Qu Y, Wang X, Essa MM and Song BJ: Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med. 53:168–188. 2021. View Article : Google Scholar : PubMed/NCBI
26	Ishibashi Y, Matsui T, Takeuchi M and Yamagishi S: Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Horm Metab Res. 45:387–390. 2013.PubMed/NCBI
27	Matsui T, Higashimoto Y and Yamagishi S: Laminin receptor mediates anti-inflammatory and anti-thrombogenic effects of pigment epithelium-derived factor in myeloma cells. Biochem Biophys Res Commun. 443:847–851. 2014. View Article : Google Scholar : PubMed/NCBI
28	Matsui T, Higashimoto Y, Nishino Y, Nakamura N, Fukami K and Yamagishi SI: RAGE-aptamer blocks the development and progression of experimental diabetic nephropathy. Diabetes. 66:1683–1695. 2017. View Article : Google Scholar : PubMed/NCBI
29	Nakamura N, Matsui T, Ishibashi Y, Sotokawauchi A, Fukami K, Higashimoto Y and Yamagishi SI: RAGE-aptamer attenuates the growth and liver metastasis of malignant melanoma in nude mice. Mol Med. 23:295–306. 2017. View Article : Google Scholar : PubMed/NCBI
30	Saika K and Sobue T: Epidemiology of breast cancer in Japan and the US. JMAJ. 52:39–44. 2009.
31	Akram M, Iqbal M, Daniyal M and Khan AU: Awareness and current knowledge of breast cancer. Biol Res. 50:332017. View Article : Google Scholar : PubMed/NCBI
32	Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL and Wolff AC: Diabetes mellitus and breast cancer outcomes: A systematic review and meta-analysis. J Clin Oncol. 29:40–46. 2011. View Article : Google Scholar : PubMed/NCBI
33	Wang M, Yang Y and Liao Z: Diabetes and cancer: Epidemiological and biological links. World J Diabetes. 11:227–238. 2020. View Article : Google Scholar : PubMed/NCBI
34	Yamagishi S, Matsui T and Fukami K: Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk. Rejuvenation Res. 18:48–56. 2015. View Article : Google Scholar : PubMed/NCBI
35	Matou-Nasri S, Sharaf H, Wang Q, Almobadel N, Rabhan Z, Al-Eidi H, Yahya WB, Trivilegio T, Ali R, Al-Shanti N and Ahmed N: Biological impact of advanced glycation endproducts on estrogen receptor-positive MCF-7 breast cancer cells. Biochim Biophys Acta Mol Basis Dis. 1863:2808–2820. 2017. View Article : Google Scholar : PubMed/NCBI
36	Lee KJ, Yoo JW, Kim YK, Choi JH, Ha TY and Gil M: Advanced glycation end products promote triple negative breast cancer cells via ERK and NF-κB pathway. Biochem Biophys Res Commun. 495:2195–2201. 2018. View Article : Google Scholar : PubMed/NCBI
37	Walter KR, Ford ME, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Phan V, La Rue AC, et al: Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat. 173:559–571. 2019. View Article : Google Scholar : PubMed/NCBI
38	Omofuma OO, Turner DP, Peterson LL, Merchant AT, Zhang J and Steck SE: Dietary advanced glycation end-products (AGE) and risk of breast cancer in the prostate, lung, colorectal and ovarian cancer screening trial (PLCO). Cancer Prev Res (Phila). 13:601–610. 2020. View Article : Google Scholar : PubMed/NCBI
39	Peterson LL, Park S, Park Y, Colditz GA, Anbardar N and Turner DP: Dietary advanced glycation end products and the risk of postmenopausal breast cancer in the national institutes of health-AARP diet and health study. Cancer. 126:2648–2657. 2020. View Article : Google Scholar : PubMed/NCBI
40	Hao L, Zhang C, Qiu Y, Wang L, Luo Y, Jin M and Zhang Y, Guo TB, Matsushima K and Zhang Y: Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett. 253:34–42. 2007. View Article : Google Scholar : PubMed/NCBI
41	Schneider BP and Sledge GW Jr: Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol. 4:181–189. 2007. View Article : Google Scholar : PubMed/NCBI
42	Dofara SG, Chang SL and Diorio C: Gene polymorphisms and circulating levels of MMP-2 and MMP-9: A review of their role in breast cancer risk. Anticancer Res. 40:3619–3631. 2020. View Article : Google Scholar : PubMed/NCBI
43	Nakamura N, Matsui T, Nishino Y, Sotokawauchi A, Higashimoto Y and Yamagishi SI: Long-term local injection of RAGE-aptamer suppresses the growth of malignant melanoma in nude mice. J Oncol. 2019:73876012019. View Article : Google Scholar : PubMed/NCBI
44	Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, et al: Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol. 165:1865–1874. 2004. View Article : Google Scholar : PubMed/NCBI
45	Yamagishi S and Imaizumi T: Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 11:2279–2299. 2005. View Article : Google Scholar : PubMed/NCBI
46	Gutsche K, Randi EB, Blank V, Fink D, Wenger RH, Leo C and Scholz CC: Intermittent hypoxia confers pro-metastatic gene expression selectively through NF-κB in inflammatory breast cancer cells. Free Radic Biol Med. 101:129–142. 2016. View Article : Google Scholar : PubMed/NCBI
47	Lewis K, Kiepas A, Hudson J, Senecal J, Ha JR, Voorand E, Annis MG, Sabourin V, Ahn R, La Selva R, et al: p66ShcA functions as a contextual promoter of breast cancer metastasis. Breast Cancer Res. 22:72020. View Article : Google Scholar : PubMed/NCBI
48	Jia L, Huang S, Yin X, Zan Y, Guo Y and Han L: Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction. Life Sci. 208:123–130. 2018. View Article : Google Scholar : PubMed/NCBI
49	Yamagishi S, Inagaki Y, Nakamura K, Abe R, Shimizu T, Yoshimura A and Imaizumi T: Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol. 37:497–506. 2004. View Article : Google Scholar : PubMed/NCBI
50	Hou J, Ge C, Cui M, Liu T, Liu X, Tian H, Zhao F, Chen T, Cui Y, Yao M, et al: Pigment epithelium-derived factor promotes tumor metastasis through an interaction with laminin receptor in hepatocellular carcinomas. Cell Death Dis. 8:e29692017. View Article : Google Scholar : PubMed/NCBI
51	Yamagishi S, Matsui T and Inoue H: Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells. Drugs Exp Clin Res. 31:227–232. 2005.PubMed/NCBI
52	Ide Y, Matsui T, Ishibashi Y, Takeuchi M and Yamagishi S: Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. Microvasc Res. 80:227–232. 2010. View Article : Google Scholar : PubMed/NCBI
53	Ishibashi Y, Matsui T, Ohta K, Tanoue R, Takeuchi M, Asanuma K, Fukami K, Okuda S, Nakamura K and Yamagishi S: PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. Microvasc Res. 85:54–58. 2013. View Article : Google Scholar : PubMed/NCBI